Despite recent advances in immunotherapy and targeted therapy, the mortality rate seen in lung cancer (LC) is the highest of all cancer forms. The recent topical coronavirus disease 19 (COVID-19) and its subsequent pandemic have resulted in over 505 million confirmed cases and approximately 6.2 million fatalities as of April 2022, with a staggering 30%-50% mortality rate seen in LC patients with COVID-19. Cancerpatients, inparticular, arehighly vulnerable to COVID-19 infection due to immunosuppression, from both the tumor and its treatments. Here we report the impact of the pandemic to be largely negative on LC treatment and research.